Neutralizing antibodies to interferon beta in patients with multiple sclerosis OriginalPaper Pages: iiI - iiII
Neutralizing antibodies to interferon beta in patients with multiple sclerosis: scientific background and clinical implications Hans-Peter HartungHuub SchellekensFrederick E. Munschauer III INTRODUCTION Pages: ii1 - ii3
Immunogenicity of recombinant human proteins: causes and consequences Huub SchellekensNicole Casadevall OriginalPaper Pages: ii4 - ii9
Biologic role of interferon beta in multiple sclerosis Alfons BilliauBernd C. KieseierHans-Peter Hartung OriginalPaper Pages: ii10 - ii14
Immunogenicity of interferon beta: differences among products Antonio BertolottoFlorian DeisenhammerPer Sölberg Sørensen OriginalPaper Pages: ii15 - ii24
Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis Timothy VartanianPer Sölberg SørensenGeorge Rice OriginalPaper Pages: ii25 - ii30
Measurement of neutralizing antibodies to interferon beta in patients with multiple sclerosis Florian DeisenhammerHuub SchellekensAntonio Bertolotto OriginalPaper Pages: ii31 - ii39
Assessment and management of neutralizing antibodies in patients with multiple sclerosis (Summary/Discussion) Hans-Peter HartungFrederick E. Munschauer III OriginalPaper Pages: ii40 - ii42